Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prilosec erosion

Executive Summary

Substitution of generic omeprazole is 12% of total scripts, 19% of new according to Jan. 5 data, Schwarz AG CEO Klaus Veitinger reported Jan. 8 at J.P. Morgan H&Q Conference in San Francisco. Schwarz subsidiary Kudco is distributing the generic of AstraZeneca's proton pump inhibitor Prilosec to mail order operations on limited basis due to manufacturing limitations (1"The Pink Sheet" Dec. 16, 2002, p. 30). Mail order aided sweeping substitution of generic fluoxetine (Lilly's Prozac), which had 80% mail service conversion rate in one week (2"The Pink Sheet" Aug. 27, 2001, p. 8). Express Scripts' 2001 Drug Trend Report predicted that, if introduced by December, generic omeprazole market share would reach 17% by end of 2003 (3"The Pink Sheet" June 17, 2002, p. 12)...

You may also be interested in...



Schwarz Omeprazole Launch Is Limited By Manufacturing Capacity

The limited manufacturing capacity of Schwarz' subsidiary Kremers Urban Development Co. means the company will supply generic omeprazole to all major pharmacy chains and drug wholesalers, but will distribute to mail order operations on a limited basis

Boston Scientific Pays More Than $1Bn For Lumenis’ Surgical Laser Business

Lumenis’ surgical business includes the MOSES laser system for minimally invasive urology surgery which will complement Boston Scientific’s LithoVue ureteroscope.

Finance Watch: Eleven Companies Reveal $1.45bn In $100m-Plus VC Deals

Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds. 

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel